Called Lunar-Cov19, the vaccine is developed by Duke-NUS Medical School and American pharmaceutical company Arcturus Therapeutics. Arcturus in a statement on Tuesday said that this first phase of the trial involved volunteers aged between 21 and 55, who were injected with a single shot of the vaccine.
